Literature DB >> 17389691

Predictive performance of the Domino, Hijazi, and Clements models during low-dose target-controlled ketamine infusions in healthy volunteers.

A R Absalom1, M Lee, D K Menon, S R Sharar, T De Smet, J Halliday, M Ogden, P Corlett, G D Honey, P C Fletcher.   

Abstract

BACKGROUND: Healthy volunteers received low-dose target-controlled infusions (TCI) of ketamine controlled by the Domino model while cognitive function tests and functional neuroimaging were performed. The aim of the current study was to assess the predictive performance of the Domino model during these studies, and compare it with that of three other ketamine models.
METHODS: Fifty-eight volunteers received ketamine administered by a TCI device on one or more occasions at target concentrations of either 50, 100, or 200 ng ml-1. At each target concentration, two or three venous blood samples were withdrawn during infusion, with a further sample after the infusion ended. Ketamine assays were performed by gas chromatography. The plasma concentration time courses predicted by the Hijazi, Clements 125, and Clements 250 models were calculated retrospectively, and the predictive performance of each of the models was assessed using Varvel methodology.
RESULTS: For the Domino model, bias, inaccuracy, wobble, and divergence were - 2.7%, 33.9%, 24.2%, and 0.1463% h-1, respectively. There was a systematic increase in performance error over time. The Clements 250 model performed best by all criteria, whereas the Hijazi model performed least well by all criteria except for bias.
CONCLUSIONS: Performance of the Domino model during control of low-dose ketamine infusions was sub-optimal. The Clements 250 model may be a better model for controlling low-dose TCI ketamine administration.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17389691      PMCID: PMC3838936          DOI: 10.1093/bja/aem063

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  39 in total

1.  Pharmacokinetics of midazolam administered by continuous intravenous infusion to intensive care patients.

Authors:  R Malacrida; M E Fritz; P M Suter; C Crevoisier
Journal:  Crit Care Med       Date:  1992-08       Impact factor: 7.598

Review 2.  Perioperative ketamine for acute postoperative pain.

Authors:  R F Bell; J B Dahl; R A Moore; E Kalso
Journal:  Cochrane Database Syst Rev       Date:  2006-01-25

3.  Pharmacokinetic model driven infusion of propofol in children.

Authors:  B Marsh; M White; N Morton; G N Kenny
Journal:  Br J Anaesth       Date:  1991-07       Impact factor: 9.166

Review 4.  The development of 'Diprifusor': a TCI system for propofol.

Authors:  J B Glen
Journal:  Anaesthesia       Date:  1998-04       Impact factor: 6.955

5.  [Optimal dosage strategies in total intravenous anesthesia using propofol and ketamine].

Authors:  J Schüttler; M Schüttler; S Kloos; J Nadstawek; H Schwilden
Journal:  Anaesthesist       Date:  1991-04       Impact factor: 1.041

6.  Psychedelic effects of ketamine in healthy volunteers: relationship to steady-state plasma concentrations.

Authors:  T A Bowdle; A D Radant; D S Cowley; E D Kharasch; R J Strassman; P P Roy-Byrne
Journal:  Anesthesiology       Date:  1998-01       Impact factor: 7.892

Review 7.  Revising a dogma: ketamine for patients with neurological injury?

Authors:  Sabine Himmelseher; Marcel E Durieux
Journal:  Anesth Analg       Date:  2005-08       Impact factor: 5.108

8.  Plasma levels of ketamine and two of its metabolites in surgical patients using a gas chromatographic mass fragmentographic assay.

Authors:  E F Domino; E K Zsigmond; L E Domino; K E Domino; S P Kothary; S E Domino
Journal:  Anesth Analg       Date:  1982-02       Impact factor: 5.108

9.  Subdissociative dose ketamine produces a deficit in manipulation but not maintenance of the contents of working memory.

Authors:  Rebekah A E Honey; Danielle C Turner; Garry D Honey; Sam R Sharar; D Kumaran; E Pomarol-Clotet; P McKenna; B J Sahakian; T W Robbins; P C Fletcher
Journal:  Neuropsychopharmacology       Date:  2003-11       Impact factor: 7.853

10.  Psychological effects of ketamine in healthy volunteers. Phenomenological study.

Authors:  E Pomarol-Clotet; G D Honey; G K Murray; P R Corlett; A R Absalom; M Lee; P J McKenna; E T Bullmore; P C Fletcher
Journal:  Br J Psychiatry       Date:  2006-08       Impact factor: 9.319

View more
  12 in total

Review 1.  Glutamatergic model psychoses: prediction error, learning, and inference.

Authors:  Philip R Corlett; Garry D Honey; John H Krystal; Paul C Fletcher
Journal:  Neuropsychopharmacology       Date:  2010-09-22       Impact factor: 7.853

2.  Phenomenologically distinct psychotomimetic effects of ketamine are associated with cerebral blood flow changes in functionally relevant cerebral foci: a continuous arterial spin labelling study.

Authors:  T A Pollak; S De Simoni; B Barimani; F O Zelaya; J M Stone; M A Mehta
Journal:  Psychopharmacology (Berl)       Date:  2015-10-05       Impact factor: 4.530

3.  Modulatory effects of ketamine, risperidone and lamotrigine on resting brain perfusion in healthy human subjects.

Authors:  Sergey Shcherbinin; Orla Doyle; Fernando O Zelaya; Sara de Simoni; Mitul A Mehta; Adam J Schwarz
Journal:  Psychopharmacology (Berl)       Date:  2015-07-31       Impact factor: 4.530

4.  Group II metabotropic glutamate receptor agonist prodrugs LY2979165 and LY2140023 attenuate the functional imaging response to ketamine in healthy subjects.

Authors:  Mitul A Mehta; Anne Schmechtig; Vasileia Kotoula; Juliet McColm; Kimberley Jackson; Claire Brittain; Sitra Tauscher-Wisniewski; Bruce J Kinon; Paul D Morrison; Thomas Pollak; Timothy Mant; Steven C R Williams; Adam J Schwarz
Journal:  Psychopharmacology (Berl)       Date:  2018-03-21       Impact factor: 4.530

5.  The Role of GluN2C-Containing NMDA Receptors in Ketamine's Psychotogenic Action and in Schizophrenia Models.

Authors:  Elizaveta Khlestova; Jon W Johnson; John H Krystal; John Lisman
Journal:  J Neurosci       Date:  2016-11-02       Impact factor: 6.167

Review 6.  Recent insights into the mode of action of memantine and ketamine.

Authors:  Jon W Johnson; Nathan G Glasgow; Nadezhda V Povysheva
Journal:  Curr Opin Pharmacol       Date:  2014-12-02       Impact factor: 5.547

7.  Ketamine perturbs perception of the flow of time in healthy volunteers.

Authors:  Jennifer T Coull; Hannah Morgan; Victoria C Cambridge; James W Moore; Francesco Giorlando; Ram Adapa; Philip R Corlett; Paul C Fletcher
Journal:  Psychopharmacology (Berl)       Date:  2011-05-21       Impact factor: 4.530

Review 8.  Ketamine: A Review of Clinical Pharmacokinetics and Pharmacodynamics in Anesthesia and Pain Therapy.

Authors:  Marko A Peltoniemi; Nora M Hagelberg; Klaus T Olkkola; Teijo I Saari
Journal:  Clin Pharmacokinet       Date:  2016-09       Impact factor: 6.447

Review 9.  Ketamine as a fast acting antidepressant: current knowledge and open questions.

Authors:  Giacomo Salvadore; Jaskaran B Singh
Journal:  CNS Neurosci Ther       Date:  2013-04-12       Impact factor: 5.243

10.  Exploring the impact of ketamine on the experience of illusory body ownership.

Authors:  Hannah L Morgan; Danielle C Turner; Philip R Corlett; Anthony R Absalom; Ram Adapa; Fernando S Arana; Jennifer Pigott; Jenny Gardner; Jessica Everitt; Patrick Haggard; Paul C Fletcher
Journal:  Biol Psychiatry       Date:  2010-10-13       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.